BCX-4208/R3421, an inhibitor of the enzyme purine nucleoside phosphorylase (PNP) being jointly developed by Roche and BioCryst Pharmaceuticals, is moving into Phase Two clinical trials for moderate to severe plaque psoriasis. Sixty patients will participate in the next trial, designed to test two different dosing levels of the orally administered experimental drug.
BCX-4208/R3421 is one of the more than 70 potential treatments currently being studied for psoriasis.
Category: Uncategorized
